Zealand Pharma Dapiglutide phase 1b shows strong weight loss, plans to follow later
Zealand announced topline results from part 2 of the phase 1b multiple ascending dose (MAD) trial of dapiglutide (long-acting GLP-1/GLP-2 receptor dual agonist) in overweight/obese participants, which showed 11.4% (placebo adjusted) weight loss, coming in higher than semaglutide, and closer to tirzepatide at a similar timepoint in the phase 3 (STEP-1 and SURMOUNT-1) trials. By targeting GLP-2 on top of GLP-1, dapiglutide aims to address low grade inflammation on top of weight loss. As such, we believe the next step is for Zealand to define which co-morbidity the candidate can address (e.g. obesity + IBD?) in order to carve out a niche within the crowded obesity pipeline. Zealand expects to communicate more on the program later this year. We reiterate our DKK 1,120 TP and Buy rating.Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.